The majority of almost 30 publications from 1992 to 1999 describe Chlamydia pneumoniae organisms in atherosclerotic lesions of various major arteries. In the first study in the United Kingdom, C. pneumoniae was found in the aorta and femoral and iliac arteries. In a subsequent study, the organism was detected in arteries of subjects as young as 15 years. In a collaborative investigation, 71% of atheromatous arteries taken at autopsy from white South African subjects were C. pneumoniae positive compared with 9% of nonatheromatous arteries. Of interest, the organisms were detected in 67% of vessels that showed only early atherosclerotic lesions (fatty streaks). C. pneumoniae was also found in the ruptured coronary artery plaque of a black South African who died of myocardial infarction, a rare event. The presence of C. pneumoniae organisms within foam and smooth muscle cells of atherosclerotic plaques is beyond doubt, but their role in atherosclerosis remains enigmatic.
Chlamydia pneumoniae is a common pathogen that causes upper and lower respiratory tract disease in humans. The first association between C. pneumoniae and coronary artery disease (CAD) was based on serologic studies in Finland in which high titers of IgG and IgA antibodies to C. pneumoniae were found significantly more often in men with myocardial infarction and chronic CAD than in age-matched randomly selected controls [1] . Subsequent serologic results have been broadly confirmatory, and the relative overall risk of coronary disease in persons with antibodies to C. pneumoniae is two-fold greater than in persons with no evidence of prior infection.
The first evidence of C. pneumoniae in atherosclerotic lesions was provided by Shor et al. [2] . By electron microscopy (EM), they observed chlamydia-like structures within sections of coronary vessels obtained at postmortem examination-findings that were confirmed by immunocytochemistry (ICC). A followup study of arteries from 36 similar subjects, utilizing a polymerase chain reaction (PCR) assay, revealed C. pneumoniae DNA in the atheromatous areas of the arteries of 20 subjects. The organisms were not detected in adjacent normal tissue or in samples from 11 control subjects with no evidence of atheroma [3] . The majority of subsequent investigations confirm the presence of C. pneumoniae in atheromatous areas of arteries (table 1) .
moniae [31] indicated that a molecular-based approach was more sensitive than other methods, including culture. Arterial samples, largely from patients undergoing reparative surgery for abdominal aortic aneurysms, were provided by A. Mansfield (St. Mary's Hospital, London). C. pneumoniae was detected in 40%-67% of the vessels examined (table 2) [11] . Vessels from liver transplant donors (supplied by B. Davidson, Royal Free Hospital, London) were used as a control group of ostensibly disease-free tissue. However, C. pneumoniae was detected in half of the iliac arteries examined and also in 1 of the 2 iliac veins from these donors. Twelve of the vascular repair specimens were also examined for the presence of C. pneumoniae by an immunofluorescence technique; 4 were unreadable because of nonspecific staining, 5 were negative, and 3 were positive. However, 1 of the unreadable specimens was positive when tested by PCR as were the 3 fluorescence-positive specimens.
The effect of age on the probability of detecting C. pneumoniae was studied by Kuo et al. [9] who, in examining coronary artery specimens, found that 1 of 22 subjects aged 15-24 years was positive by ICC, PCR, or both. In collaboration with M. Rose and M. Yacoub (Harefield Hospital, Hertfordshire, UK), we investigated this aspect in greater detail by examining samples from the aorta, pulmonary artery, and atrium of heart transplant donors (age range, 4 months-60 years). PCR assay results revealed C. pneumoniae in tissues of donors у15 years old but not in younger children [24] .
Studies in South African Patients
In a collaborative study with A. Shor and J. Phillips (National Centre for Occupational Health, Johannesburg), 35 autopsy specimens (largely aortic, carotid, and iliac arteries) from 25 subjects were examined by EM (22 specimens), ICC (7 specimens), and PCR assay (all specimens) [25] . C. pneumoniae was detected in 17 (71%) of 24 atheromatous arteries but in only 1 (9%) of 11 nonatheromatous vessels in 4 of 6 samples exhibiting early atheromatous changes (fatty streaks), and in 1 sample from a 20-year-old subject. If C. pneumoniae had been detected solely in the advanced lesions of elderly subjects, it would likely have gained entry to preexisting atheromatous lesions and could then be regarded only as a "bystander." Detection in early lesions in young subjects, however, opens up the possibility of a primary etiologic role. Myocardial infarction is rare in black South Africans. However, a 39-year-old black South African man, who had no recognized risk factors for CAD except hypertension, died of a myocardial infarct. He previously had been infected with C. pneumoniae, as indicated by serology, and the left anterior descending branch of the coronary artery contained a ruptured plaque that was identified as C. pneumoniae positive by ICC, EM, and PCR [32] . Organisms were found in smooth muscle cells, foam cells, and interstitially but not in adjacent unaffected tissue. C. pneumoniae was detected also in the left ventricular myocardium in an area of the infarct; debris from the ruptured plaque had possibly been deposited in the muscle.
Discussion
C. pneumoniae is a plausible candidate for causing atherosclerosis. It is common and widespread and infection is often asymptomatic and untreated, thus increasing the opportunity for hematogenous spread. C. pneumoniae has been detected in peripheral blood monocytes [33] , which may be the mode of transmission for the organism to the coronary and other arteries. Infection and the first atheromatous changes both occur early in life, and reinfection is common, increasing the life-long risk for arteries to become affected. C. pneumoniae infection and CAD both affect men more often than women. Other species in the genus Chlamydia cause chronic inflammatory con-ditions (e.g., trachoma and the sequelae of pelvic inflammatory disease in women) and established atherosclerosis is essentially chronic in nature.
There is now overwhelming evidence from studies in various parts of the world for the presence of C. pneumoniae organisms in atherosclerotic tissue. Investigators who fail to find the organisms should check their materials and methods and perhaps most profitably enlist the help of those who have been successful. The question of how much sample should be examined before regarding it as chlamydia negative is one that is very difficult to resolve. The amount of C. pneumoniae in tissue and the extent to which it accumulates uniformly or otherwise is uncertain and requires further investigation; in addition, inhibitors of the PCR reaction in the tissue should be considered and eliminated where possible. Conversely, the specificity of components identified as C. pneumoniae antigens by ICC staining has been questioned [34] , and this is a particular problem in studies where PCR and ICC results for the same samples are discordant. It is evident that some positive and negative results should be viewed with caution.
The involvement of C. pneumoniae in atherosclerosis remains enigmatic. The organism might travel via peripheral blood monocytes and itself create a focus of arterial damage for subsequent development of an atherosclerotic plaque. Alternatively, infected monocytes could migrate to an already inflamed area of the arterial wall, and hence have no role in the initiation of the pathologic process. These two propositions may not be mutually exclusive, but the first will be particularly difficult to prove. It is of note that C. pneumoniae is first detected in human vessels at about the age when atheromatous lesions (fatty streaks) might be expected to appear, although it does not follow that there is an etiologic association. The likelihood of such an association might be determined, as discussed previously [25] , by considering the following factors: the plausibility of the hypothesis, the strength of the association determined by quantitative rather than qualitative estimations of the organisms present, further detailed microbiologic/histopathologic assessments of very early atherosclerotic changes, more comprehensive investigations to determine the involvement of other organisms, more evidence from animal models, the outcome of antibiotic trials (particularly those in young subjects), and the outcome of future vaccine trials.
